Randomized controlled trialHumanClinical Trial, Phase III
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
The lancet. Diabetes & endocrinology, 2026 Aug. Buse JB, Bajaj HS, Dalskov SM and 9 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The lancet. Diabetes & endocrinology
Published
2026 Aug
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansDiabetes Mellitus, Type 2SemaglutideGlucagon-Like PeptidesFemaleDouble-Blind MethodMaleMiddle AgedHypoglycemic AgentsAgedBlood GlucoseAdult
Other papers on Cagrilintide
Randomized controlled trial · 2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Journal article · 2025Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page